Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study
Yong Shao, Zhe Lu, Yuyanan Zhang, Xueping Wang · 2026
Read Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study by Yong Shao, Zhe Lu, Yuyanan Zhang, Xueping Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13590559.txt.
Description
Yong Shao and three colleagues mine records from one hospital to weigh side effects of antipsychotic drugs used for schizophrenia. Their focus is high prolactin, a hormone shift that can harm sexual health, fertility, and bones and can push patients to quit their drugs. They also tracked shaking and stiffness, a second common side effect, plus related hormone levels.
Women with schizophrenia had the highest rate of high prolactin, near one in five of those tested. Risk climbed with certain drugs, notably risperidone and its kin, and fell with others. Stiffness and shaking grew more common as prolactin rose, yet one low prolactin drug still carried high shaking risk. Shao and the team built a receptor based score that tracked prolactin risk well, to guide drug choice.
Catalog record
| CREATOR | Yong Shao, Zhe Lu, Yuyanan Zhang, Xueping Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |